450 related articles for article (PubMed ID: 19075263)
1. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
Ahmadi T; Schuster SJ
J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
[No Abstract] [Full Text] [Related]
2. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia.
Schierl M; Foedinger D; Geissler K; Rappersberger K; Feldmann R
Eur J Dermatol; 2008; 18(6):717-8. PubMed ID: 19049939
[No Abstract] [Full Text] [Related]
5. Changing the way we think about chronic lymphocytic leukemia.
Lin TS; Grever MR; Byrd JC
J Clin Oncol; 2005 Jun; 23(18):4009-12. PubMed ID: 15767640
[No Abstract] [Full Text] [Related]
6. Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy.
Garratty G; Petz LD
Br J Haematol; 2007 Nov; 139(4):622-3. PubMed ID: 17979948
[No Abstract] [Full Text] [Related]
7. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies in chronic lymphocytic leukemia.
Ferrajoli A; Faderl S; Keating MJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
[TBL] [Abstract][Full Text] [Related]
9. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
10. [Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].
Telek B; Batár P; Uvardy M
Orv Hetil; 2005 Aug; 146(34):1791-3. PubMed ID: 16184881
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
12. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
Borthakur G; O'Brien S; Wierda WG; Thomas DA; Cortes JE; Giles FJ; Kantarjian HM; Lerner S; Keating MJ
Br J Haematol; 2007 Mar; 136(6):800-5. PubMed ID: 17341265
[TBL] [Abstract][Full Text] [Related]
13. Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
Nabhan C
Clin Cancer Res; 2008 Jul; 14(13):4353. PubMed ID: 18594019
[No Abstract] [Full Text] [Related]
14. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
[TBL] [Abstract][Full Text] [Related]
15. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
[TBL] [Abstract][Full Text] [Related]
16. A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
Haines I; Elliott P; Stanley R
Intern Med J; 2009 Apr; 39(4):269-71. PubMed ID: 19402870
[No Abstract] [Full Text] [Related]
17. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszyńska A; Roliński J
Leuk Res; 2007 Mar; 31(3):411-2. PubMed ID: 16978694
[No Abstract] [Full Text] [Related]
18. Fludarabine in chronic lymphocytic leukaemia.
Elter T; Hallek M; Engert A
Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
[TBL] [Abstract][Full Text] [Related]
19. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
Abbott BL
Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
[TBL] [Abstract][Full Text] [Related]
20. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E
Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]